Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Deep dives into peptide science — evidence-graded, honestly reported
HPTA recovery after testosterone therapy takes far longer than forums claim. Established PCT has limits, and peptides offer a mechanistically compelling but clinically unproven layer on top.
Exogenous testosterone suppresses the hypothalamic-pituitary-testicular axis at every level. Recovery is measured in months to years, not weeks. This article maps the clinical timeline, examines where Kisspeptin-10, triptorelin, and GH secretagogues fit, and is honest about what the evidence does and does not support.
Comprehensive outcome research with safety data and practical protocol references
Detailed compound profiles with mechanisms, safety data, and dosing protocols
Evidence-based supplement stacks designed to support your peptide protocols
Two sister peptides from the same Cold War lab, one calms the emotional floor, the other raises the cognitive ceiling. The mechanistic case for stacking them is architecturally compelling. The clinical evidence for the combination doesn't exist yet.
Selank and Semax are sister heptapeptides engineered with the same glyproline stability tail but from opposite parent molecules, tuftsin (immune) and ACTH (stress). They converge on BDNF through completely different upstream pathways, covering complementary neurochemical territory. This article examines the mechanistic case for combining them, the cofactors that determine whether either signal lands, and where the evidence stops short.
From Dihexa's synaptogenic hammer to Cerebrolysin's clinical track record — five realities of the peptide cognition frontier, and the regulatory minefield around them.
An evidence-based exploration of memory-management peptides including Dihexa, Semax, Selank, P21, and Cerebrolysin. We examine synaptogenic potency claims alongside oncogenic risk, the FDA's 2024 compounding ban, and where clinical evidence ends and biohacking speculation begins.
An ACTH-derived heptapeptide that upregulates BDNF, modulates the Default Mode Network, and delivers 20-24 hours of neuroprotection per dose — without a single hormonal side effect.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) engineered from the ACTH(4-10) fragment. It upregulates Brain-Derived Neurotrophic Factor, inhibits enkephalinase, and suppresses neuroinflammation — delivering cognitive enhancement, stroke recovery support, and neuroprotection through a single intranasal molecule.
The biochemical cofactors your body needs to support Semax therapy.
Evidence-based supplement companion for Semax — an ACTH-derived heptapeptide that upregulates BDNF, modulates the Default Mode Network, and delivers 20-24 hours of neuroprotection per dose — without a single hormonal side effect.
The biochemical cofactors your body needs to support Selank therapy.
Evidence-based supplement companion for Selank — a tuftsin-derived heptapeptide that delivers benzodiazepine-level anxiety relief without sedation, dependence, or cognitive fog — while simultaneously boosting immune defence.
The biochemical cofactors your body needs to support Pinealon therapy.
Evidence-based supplement companion for Pinealon — a three-amino-acid peptide that bypasses the blood-brain barrier, enters the nucleus, and directly modulates gene expression for neuroprotection.
35+
Articles
18
Categories